Similarly, in validation cohort, the overall survival and disease-free survival for HCC patients with high YMO1 expression are much better than patients with low YMO1 expression (P = 0.014 and P = 0.023, respectively) (Figure 2B). Here, EPB41L5 is linked to hepatocellular carcinoma.